{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:56:33Z","timestamp":1778309793604,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T00:00:00Z","timestamp":1301529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00228-011-1031-6","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T11:27:37Z","timestamp":1301484457000},"page":"941-951","source":"Crossref","is-referenced-by-count":28,"title":["Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case\u2013control study in a large population-based German database"],"prefix":"10.1007","volume":"67","author":[{"given":"Kathrin","family":"Jobski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid","family":"Behr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edeltraut","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"issue":"3","key":"1031_CR1","first-page":"537","volume":"94","author":"C Gasse","year":"2005","unstructured":"Gasse C, Hollowell J, Meier CR, Haefeli WE (2005) Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 94(3):537\u2013543","journal-title":"Thromb Haemost"},{"issue":"489","key":"1031_CR2","first-page":"312","volume":"53","author":"J Hollowell","year":"2003","unstructured":"Hollowell J, Ruigomez A, Johansson S, Wallander MA, Garcia-Rodriguez LA (2003) The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Br J Gen Pract 53(489):312\u2013314","journal-title":"Br J Gen Pract"},{"issue":"2","key":"1031_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11239-007-0048-2","volume":"25","author":"JD Lindh","year":"2008","unstructured":"Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A (2008) Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 25(2):151\u2013159","journal-title":"J Thromb Thrombolysis"},{"issue":"9025","key":"1031_CR4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","volume":"348","author":"G Palareti","year":"1996","unstructured":"Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D\u2019Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348(9025):423\u2013428","journal-title":"Lancet"},{"issue":"13","key":"1031_CR5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.153.13.1557","volume":"153","author":"FJ Meer van der","year":"1993","unstructured":"Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153(13):1557\u20131562","journal-title":"Arch Intern Med"},{"issue":"15","key":"1031_CR6","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.296.15.1858","volume":"296","author":"DS Budnitz","year":"2006","unstructured":"Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15):1858\u20131866","journal-title":"JAMA"},{"issue":"7456","key":"1031_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15\u201319","journal-title":"BMJ"},{"issue":"2","key":"1031_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00002018-200629020-00006","volume":"29","author":"CS Hooft van der","year":"2006","unstructured":"Van der Hooft CS, Sturkenboom MC, Van Grootheest K, Kingma HJ, Stricker BH (2006) Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 29(2):161\u2013168","journal-title":"Drug Saf"},{"key":"1031_CR9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/978-3-642-01080-4_15","volume-title":"Arzneiverordnungs-report 2009","author":"L Hein","year":"2009","unstructured":"Hein L (2009) Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe U, Paffrath D (eds) Arzneiverordnungs-report 2009. Springer, Berlin, pp 381\u2013395"},{"issue":"3","key":"1031_CR10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00228-004-0740-5","volume":"60","author":"M Ufer","year":"2004","unstructured":"Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G (2004) Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 60(3):173\u2013182","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1031_CR11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","volume":"44","author":"M Ufer","year":"2005","unstructured":"Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44(12):1227\u20131246","journal-title":"Clin Pharmacokinet"},{"key":"1031_CR12","unstructured":"Meda Pharma (2009) Marcumar fachinformation www.fachinfo.de . Accessed 2 June 2010"},{"issue":"6","key":"1031_CR13","first-page":"1052","volume":"100","author":"M Beinema","year":"2008","unstructured":"Beinema M, Brouwers JR, Schalekamp T, Wilffert B (2008) Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 100(6):1052\u20131057","journal-title":"Thromb Haemost"},{"issue":"6 Suppl","key":"1031_CR14","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):160S\u2013198S","journal-title":"Chest"},{"key":"1031_CR15","unstructured":"ABDA Datenbank (2009) Interaktionsmonographien. ABDA-Bundesvereinigung Deutscher Apothekerverb\u00e4nde. Accessed 5 December 2009"},{"key":"1031_CR16","unstructured":"Drugdex evaluations (2008) Micromedex healthcare series http:\/\/www.thomsonhc.com . Accessed 29 August 2008"},{"issue":"6","key":"1031_CR17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199630060-00002","volume":"30","author":"S Harder","year":"1996","unstructured":"Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30(6):416\u2013444","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1031_CR18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1503\/cmaj.070186","volume":"177","author":"JA Delaney","year":"2007","unstructured":"Delaney JA, Opatrny L, Brophy JM, Suissa S (2007) Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177(4):347\u2013351","journal-title":"CMAJ"},{"issue":"2","key":"1031_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archinte.165.2.189","volume":"165","author":"M Battistella","year":"2005","unstructured":"Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A (2005) Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 165(2):189\u2013192","journal-title":"Arch Intern Med"},{"issue":"7","key":"1031_CR20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11606-005-0113-5","volume":"20","author":"JJ Glasheen","year":"2005","unstructured":"Glasheen JJ, Fugit RV, Prochazka AV (2005) The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med 20(7):653\u2013656","journal-title":"J Gen Intern Med"},{"issue":"8","key":"1031_CR21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.18553\/jmcp.2006.12.8.640","volume":"12","author":"K Zhang","year":"2006","unstructured":"Zhang K, Young C, Berger J (2006) Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm 12(8):640\u2013648","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"1031_CR22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1538-7836.2008.02844.x","volume":"6","author":"FJ Penning-van Beest","year":"2008","unstructured":"Penning-van Beest FJ, Koerselman J, Herings RM (2008) Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost 6(2):284\u2013290","journal-title":"J Thromb Haemost"},{"issue":"5\u20136","key":"1031_CR23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00228-005-0947-0","volume":"61","author":"FJ Penning-van Beest","year":"2005","unstructured":"Penning-van Beest FJ, Erkens J, Petersen KU, Koelz HR, Herings R (2005) Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 61(5\u20136):439\u2013444","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1031_CR24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1055\/s-0037-1613289","volume":"88","author":"LE Visser","year":"2002","unstructured":"Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH (2002) Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 88(5):705\u2013710","journal-title":"Thromb Haemost"},{"issue":"6","key":"1031_CR25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1067\/mcp.2002.124470","volume":"71","author":"LE Visser","year":"2002","unstructured":"Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH (2002) Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 71(6):496\u2013502","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1031_CR26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.1545","volume":"17","author":"I Pigeot","year":"2008","unstructured":"Pigeot I, Ahrens W (2008) Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 17(3):215\u2013223","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1031_CR27","unstructured":"Schink, T, Behr, S, Garbe E (2009) Externe Validierung von Verschreibungsdaten nichtsteroidaler Antirheumatika anhand des Arzneiverordnungsreports 54. Jahrestagung der Deutschen Gesellschaft f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie (gmds), 9 September 2009"},{"issue":"7","key":"1031_CR28","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/pds.1973","volume":"19","author":"S Behr","year":"2010","unstructured":"Behr S, Andersohn F, Garbe E (2010) Risk of intracerebral hemorrhage associated with phenprocoumon exposure: a nested case-control study in a large population-based German database. Pharmacoepidemiol Drug Saf 19(7):722\u2013730","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1031_CR29","first-page":"268","volume":"102","author":"G Palareti","year":"2009","unstructured":"Palareti G, Cosmi B (2009) Bleeding with anticoagulation therapy\u2014who is at risk, and how best to identify such patients. Thromb Haemost 102(2):268\u2013278","journal-title":"Thromb Haemost"},{"key":"1031_CR30","first-page":"111","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ, Greenland S, Lash TL (2008) Case-control studies. In: Rothman KJ, Greenland S (eds) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia, pp 111\u2013127"},{"issue":"8","key":"1031_CR31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00228-004-0812-6","volume":"60","author":"V Bergk","year":"2004","unstructured":"Bergk V, Gasse C, Schnell R, Haefeli WE (2004) Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 60(8):595\u2013602","journal-title":"Eur J Clin Pharmacol"},{"key":"1031_CR32","unstructured":"Rote Liste (2010) Cumarin-(4-Hydroxy)-Derivate Rote Liste http:\/\/www.rote-liste.de . Accessed 2 June 2010"},{"key":"1031_CR33","unstructured":"Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/table.asp . Accessed 2 June 2010"},{"key":"1031_CR34","unstructured":"Multidisciplinary Medication Management Project (2001) Top ten dangerous drug interactions in long-term care AMDA annual meeting http:\/\/www.scoup.net\/m3project\/topten\/ . Accessed 2 June 2010"},{"issue":"5","key":"1031_CR35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.2008.150","volume":"84","author":"H Schelleman","year":"2008","unstructured":"Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84(5):581\u2013588","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1031_CR36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1067\/mcp.2001.115723","volume":"69","author":"FJ Penning-van Beest","year":"2001","unstructured":"Penning-van Beest FJ, van Meegen E, Rosendaal FJ, Stricker BH (2001) Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 69(6):451\u2013457","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1031_CR37","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1345\/aph.1M284","volume":"43","author":"TC Cheetham","year":"2009","unstructured":"Cheetham TC, Levy G, Niu F, Bixler F (2009) Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 43(11):1765\u20131773","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1031_CR38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1345\/aph.1C157","volume":"37","author":"EA Knijff-Dutmer","year":"2003","unstructured":"Knijff-Dutmer EA, Schut GA, van de Laar MA (2003) Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother 37(1):12\u201316","journal-title":"Ann Pharmacother"},{"issue":"7","key":"1031_CR39","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinte.165.7.784","volume":"165","author":"K Buresly","year":"2005","unstructured":"Buresly K, Eisenberg MJ, Zhang X, Pilote L (2005) Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165(7):784\u2013789","journal-title":"Arch Intern Med"},{"issue":"4","key":"1031_CR40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1378\/chest.07-2627","volume":"133","author":"SG Johnson","year":"2008","unstructured":"Johnson SG, Rogers K, Delate T, Witt DM (2008) Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 133(4):948\u2013954","journal-title":"Chest"},{"issue":"6","key":"1031_CR41","first-page":"1076","volume":"100","author":"T Schalekamp","year":"2008","unstructured":"Schalekamp T, Klungel OH, Souverein PC, de Boer A (2008) Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 100(6):1076\u20131083","journal-title":"Thromb Haemost"},{"issue":"16","key":"1031_CR42","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170(16):1433\u20131441","journal-title":"Arch Intern Med"},{"issue":"9706","key":"1031_CR43","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R Sorensen","year":"2009","unstructured":"Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374(9706):1967\u20131974","journal-title":"Lancet"},{"issue":"5","key":"1031_CR44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00007611-200005000-00001","volume":"93","author":"K Demirkan","year":"2000","unstructured":"Demirkan K, Stephens MA, Newman KP, Self TH (2000) Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 93(5):448\u2013454","journal-title":"South Med J"},{"issue":"2","key":"1031_CR45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0037-1616088","volume":"86","author":"FJ Penning-van Beest","year":"2001","unstructured":"Penning-van Beest FJ, Van Meegen E, Rosendaal FR, Stricker BH (2001) Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 86(2):569\u2013574","journal-title":"Thromb Haemost"},{"issue":"7","key":"1031_CR46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archinternmed.2010.37","volume":"170","author":"HD Fischer","year":"2010","unstructured":"Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A (2010) Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 170(7):617\u2013621","journal-title":"Arch Intern Med"},{"issue":"5","key":"1031_CR47","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1345\/aph.1K605","volume":"42","author":"DN Carroll","year":"2008","unstructured":"Carroll DN, Carroll DG (2008) Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother 42(5):680\u2013685","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1031_CR48","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1592\/phco.2005.25.6.904","volume":"25","author":"LM Arnold","year":"2005","unstructured":"Arnold LM, Nissen LR, Ng TM (2005) Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy 25(6):904\u2013907","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1031_CR49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1345\/aph.1E179","volume":"39","author":"DH Elbe","year":"2005","unstructured":"Elbe DH, Chang SW (2005) Moxifloxacin-warfarin interaction: a series of five case reports. Ann Pharmacother 39(2):361\u2013364","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1031_CR50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1096-8652(200001)63:1<28::AID-AJH6>3.0.CO;2-J","volume":"63","author":"RJ Ellis","year":"2000","unstructured":"Ellis RJ, Mayo MS, Bodensteiner DM (2000) Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 63(1):28\u201331","journal-title":"Am J Hematol"},{"issue":"4","key":"1031_CR51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0953-6205(03)00067-0","volume":"14","author":"KA O\u2019Connor","year":"2003","unstructured":"O\u2019Connor KA, O\u2019Mahony D (2003) The interaction of moxifloxacin and warfarin in three elderly patients. Eur J Intern Med 14(4):255\u2013257","journal-title":"Eur J Intern Med"},{"issue":"7","key":"1031_CR52","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/SMJ.0b013e318073c7ee","volume":"100","author":"RS Vadlamudi","year":"2007","unstructured":"Vadlamudi RS, Smalligan RD, Ismail HM (2007) Interaction between warfarin and levofloxacin: case series. South Med J 100(7):720\u2013724","journal-title":"South Med J"},{"issue":"12","key":"1031_CR53","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.amjmed.2005.06.066","volume":"118","author":"LF Stroud","year":"2005","unstructured":"Stroud LF, Mamdami MM, Kopp A, Bell CM (2005) The safety of levofloxacin in elderly patients on warfarin. Am J Med 118(12):1417","journal-title":"Am J Med"},{"key":"1031_CR54","unstructured":"Bayer Schering Pharma (2011) Xarelto 10\u00a0mg Filmtabletten Fachinformation www.fachinfo.de . Accessed 15 February 2011"},{"key":"1031_CR55","unstructured":"Boehringer Ingelheim (2011) Pradaxa 110\u00a0mg Hartkapseln Fachinformation www.fachinfo.de . Accessed 15 February 2011"},{"issue":"7","key":"1031_CR56","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1742-1241.2009.02286.x","volume":"64","author":"JM Walenga","year":"2010","unstructured":"Walenga JM, Adiguzel C (2010) Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 64(7):956\u2013967","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1031_CR57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1525-1497.1998.00096.x","volume":"13","author":"DA McMahan","year":"1998","unstructured":"McMahan DA, Smith DM, Carey MA, Zhou XH (1998) Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 13(5):311\u2013316","journal-title":"J Gen Intern Med"},{"issue":"5","key":"1031_CR58","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1378\/chest.130.5.1390","volume":"130","author":"TI Shireman","year":"2006","unstructured":"Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF (2006) Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130(5):1390\u20131396","journal-title":"Chest"},{"issue":"5","key":"1031_CR59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0002-9343(99)00267-3","volume":"107","author":"RH White","year":"1999","unstructured":"White RH, Beyth RJ, Zhou H, Romano PS (1999) Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 107(5):414\u2013424","journal-title":"Am J Med"},{"issue":"4","key":"1031_CR60","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","volume":"20","author":"NA Limdi","year":"2009","unstructured":"Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M (2009) Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20(4):912\u2013921","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1031_CR61","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archneur.65.9.noc70105","volume":"65","author":"H Hallevi","year":"2008","unstructured":"Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC (2008) Anticoagulation after cardioembolic stroke: to bridge or not to bridge? Arch Neurol 65(9):1169\u20131173","journal-title":"Arch Neurol"},{"issue":"21","key":"1031_CR62","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.jacc.2009.12.056","volume":"55","author":"C Tompkins","year":"2010","unstructured":"Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA (2010) Dual antiplatelet therapy and heparin \"bridging\" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 55(21):2376\u20132382","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1031_CR63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1503\/cmaj.080171","volume":"179","author":"N Oake","year":"2008","unstructured":"Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C (2008) Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 179(3):235\u2013244","journal-title":"CMAJ"},{"issue":"10","key":"1031_CR64","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095\u20131106","journal-title":"Arch Intern Med"},{"issue":"9","key":"1031_CR65","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00228-006-0158-3","volume":"62","author":"CM Schwabedissen zu","year":"2006","unstructured":"Zu Schwabedissen CM, Mevissen V, Schmitz F, Woodruff S, Langebartels G, Rau T, Zerres K, Hoffmann R, Ortlepp JR (2006) Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. Eur J Clin Pharmacol 62(9):713\u2013720","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1031_CR66","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1016\/j.amjmed.2006.06.030","volume":"120","author":"CM Bell","year":"2007","unstructured":"Bell CM, Stroud LF, Kopp A (2007) The safety of levofloxacin in patients on warfarin\u2014reply. Am J Med 120(4):E15\u2013E16","journal-title":"Am J Med"},{"issue":"4","key":"1031_CR67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323\u2013337","journal-title":"J Clin Epidemiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-011-1031-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1031-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T22:14:11Z","timestamp":1637446451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1031-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1031-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]}}}